Values First Advisors Inc. Sells 118 Shares of Eli Lilly and Company $LLY

Values First Advisors Inc. lessened its position in Eli Lilly and Company (NYSE:LLY) by 24.5% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 363 shares of the company’s stock after selling 118 shares during the quarter. Values First Advisors Inc.’s holdings in Eli Lilly and Company were worth $283,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Hobbs Wealth Management LLC boosted its stake in Eli Lilly and Company by 0.8% during the first quarter. Hobbs Wealth Management LLC now owns 1,459 shares of the company’s stock worth $1,205,000 after buying an additional 12 shares during the period. Hixon Zuercher LLC boosted its stake in Eli Lilly and Company by 0.7% during the first quarter. Hixon Zuercher LLC now owns 1,789 shares of the company’s stock worth $1,477,000 after buying an additional 12 shares during the period. O Brien Wealth Partners LLC boosted its stake in Eli Lilly and Company by 25.5% during the first quarter. O Brien Wealth Partners LLC now owns 59 shares of the company’s stock worth $49,000 after buying an additional 12 shares during the period. Ascent Capital Management LLC boosted its holdings in Eli Lilly and Company by 2.5% during the 1st quarter. Ascent Capital Management LLC now owns 495 shares of the company’s stock valued at $409,000 after acquiring an additional 12 shares during the period. Finally, Cottage Street Advisors LLC boosted its holdings in Eli Lilly and Company by 2.5% during the 1st quarter. Cottage Street Advisors LLC now owns 533 shares of the company’s stock valued at $440,000 after acquiring an additional 13 shares during the period. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 1.0%

Shares of Eli Lilly and Company stock opened at $818.45 on Friday. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $935.63. The company has a 50 day moving average of $749.52 and a 200 day moving average of $766.23. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The company has a market capitalization of $774.63 billion, a P/E ratio of 53.49, a P/E/G ratio of 1.18 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter in the previous year, the firm earned $3.92 earnings per share. The firm’s quarterly revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Insider Buying and Selling

In related news, EVP Daniel Skovronsky acquired 1,000 shares of the business’s stock in a transaction on Tuesday, August 12th. The shares were bought at an average price of $634.40 per share, with a total value of $634,400.00. Following the completion of the acquisition, the executive vice president owned 137,660 shares in the company, valued at $87,331,504. This trade represents a 0.73% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO David A. Ricks acquired 1,632 shares of the business’s stock in a transaction on Tuesday, August 12th. The shares were bought at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the acquisition, the chief executive officer owned 546,601 shares of the company’s stock, valued at $352,431,926.77. This represents a 0.30% increase in their position. The disclosure for this purchase can be found here. Insiders have bought 4,514 shares of company stock valued at $2,894,841 over the last ninety days. 0.13% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

LLY has been the subject of a number of research analyst reports. Wall Street Zen cut Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 20th. Guggenheim reissued a “buy” rating and issued a $948.00 price objective on shares of Eli Lilly and Company in a research note on Thursday. The Goldman Sachs Group raised their price objective on shares of Eli Lilly and Company from $876.00 to $879.00 and gave the company a “buy” rating in a research note on Friday, October 10th. Daiwa Capital Markets lowered shares of Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 price objective for the company. in a research note on Sunday, August 17th. Finally, Berenberg Bank reissued a “hold” rating and issued a $830.00 price objective (down previously from $970.00) on shares of Eli Lilly and Company in a research note on Wednesday, September 17th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $939.12.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.